Drug Topics

FEBRUARY 29, 2024

Physician assistants have pulled well ahead of pharmacists in a recent listing of top jobs in the health care profession.

200

200

STAT

FEBRUARY 29, 2024

The outage caused by the Change Healthcare cyberattack could last weeks, a top UnitedHealth executive suggested in a Tuesday conference call with hospital cybersecurity officers, according to a recording obtained by STAT. UnitedHealth Group Chief Operating Officer Dirk McMahon said the company is setting up a loan program to help providers who can’t submit insurance claims while Change is offline.

Insurance 145

Insurance Hospitals 145

Drug Topics

FEBRUARY 29, 2024

Viking Therapeutics’ VK2735 met both of its primary and secondary endpoints in the VENTURE trial, demonstrating statistically significant reductions in body weight compared to placebo.

148

148

STAT

FEBRUARY 29, 2024

LEXINGTON, Mass. — New obesity drugs like Wegovy and Zepbound are currently taken once a week, indefinitely. But what if they could be taken once a year instead, like a vaccine? That’s a question that Novo Nordisk, the pharma company behind Wegovy, is exploring as it faces increased competition from other drugmakers aiming to develop similar GLP-1-based treatments for obesity.

Vaccines 145

Vaccines 145

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Fierce Healthcare

FEBRUARY 29, 2024

Telemedicine clinic Virta Health believes its members can achieve significant and sustained improvement in weight loss, even if a patient has stopped taking a GLP-1 drug, a newly released paper in | A new study in Diabetes Therapy from Virta Health says the company's carbohydrate restricted nutrition therapy allows patients who no longer want a GLP-1 prescription to still keep the weight off.

138

138

STAT

FEBRUARY 29, 2024

More than 1 billion people — or one in eight people worldwide — are now estimated to have obesity, a new study finds. Obesity rates grew particularly fast among children and teens, quadrupling from 1990 to 2022, the latest year the analysis looked at, while rates among adults more than doubled. That comes to 159 million children and teens with obesity, and 879 million adults, according to the study, published Thursday in the Lancet and conducted by the NCD Risk Factor Collaboration

144

144

STAT

FEBRUARY 29, 2024

Pfizer spent more than four hours Thursday laying out its oncology program to investors. But the company also spent some time talking about the effects of the Inflation Reduction Act on its pipeline. The drug giant, which is facing investor dissatisfaction after a year in which its stock dropped 44%, said it would be focusing on drugs that are based on proteins, not small molecule pills as it has traditionally developed.

143

143

Fierce Healthcare

FEBRUARY 29, 2024

Two of Trinity Health’s affiliate hospitals mounted lawsuits against a large anesthesia group alleging that non-compete and non-solicitation clauses included in its providers’ contracts restrict co | The latest pushback against large anesthesiology groups' market power and practices alleges "millions of dollars" in damages for each hospital due to "exorbitant" payment demands.

Hospitals 136

Hospitals 136

STAT

FEBRUARY 29, 2024

The new vaccines that protect older adults against respiratory syncytial virus, or RSV, may be linked to a small increased risk of developing Guillain-Barré syndrome, new data from the Centers for Disease Control and Prevention and the Food and Drug Administration suggest. At a meeting Thursday of the Advisory Committee on Immunization Practices, vaccine safety experts from the two agencies presented data that showed what appears to be an elevated rate of GBS, as the condition is called, am

Vaccines 142

Vaccines Immunization 142

Fierce Healthcare

FEBRUARY 29, 2024

Elsevier Health has launched an generative AI-driven version of its flagship clinical decision support tool, ClinicalKey, in partnership with AI company OpenEvidence. | The tool, developed with several key partners, offers an advanced conversational search interface to help doctors find important medical information at the point of care. More than 30,000 doctors across the U.S. have tested the underlying AI technology.

125

125

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

STAT

FEBRUARY 29, 2024

Biotech is awash in PIPEs. The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year. Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year.

140

140

Pharmaceutical Technology

FEBRUARY 29, 2024

India’s Tata Institute has developed a tablet combining resveratrol and copper that has the potential to prevent the recurrence of cancer.

143

143

STAT

FEBRUARY 29, 2024

As pharma companies wrestle with how and when to use wearables and other digital technologies to measure how their experimental drugs impact patients, clinical research giant Icon has acquired HumanFirst, which helps companies answer exactly those sorts of questions. Founded in 2017, HumanFirst maintains a meticulously organized library of digital measurement tools, their underlying evidence, and information about how they have been used in clinical trials.

Pharmaceutical Companies 138

Pharmaceutical Companies Pharmaceutical Companies 138

Fierce Healthcare

FEBRUARY 29, 2024

Long-term commitment and a willingness to stomach both upfront and last-mile burdens are the price of admission for millions in analytics-based cost savings and revenue enhancements. | The nonprofit health system partnered with Health Catalyst on eight years of performance improvement initiatives targeting length of stay, care management, ED utilization and other costly focus areas.

125

125

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

STAT

FEBRUARY 29, 2024

Pfizer has a big problem. The drug giant hopes that new drugs to treat cancer are the solution. Shares in the drugmaker fell 44% last year, and it now has a market capitalization of only $150 billion — a quarter that of Eli Lilly and half that of longtime rival Merck. In March of last year the company announced that it would spend $43 billion to buy Seagen , a maker of a hot category of oncology medicines called antibody-drug conjugates.

136

136

pharmaphorum

FEBRUARY 29, 2024

Explore how innovation in healthcare can be scaled across hospitals and nations, driving transformation through research & development, biotech collaborations, and fostering start-ups in the industry.

Hospitals 121

Hospitals 121

STAT

FEBRUARY 29, 2024

Jean Cui, a former Pfizer chemist whose last company was sold to Bristol Myers Squibb for $4 billion, has raised $173 million from a coalition of top biotech investors for her new company, BlossomHill Therapeutics. BlossomHill is preparing to start human clinical studies of potential medicines that could someday treat blood cancer and lung cancer. It announced Thursday that it has raised $100 million from firms including Colt Ventures, Cormorant Asset Management, and OrbiMed.

133

133

Fierce Pharma

FEBRUARY 29, 2024

As Johnson & Johnson's U.S. exclusivity period on its immunology blockbuster Stelara ticks away, another biosimilar player has lined up for the piece of the drug's sales pie. | As Johnson & Johnson's U.S. exclusivity period on Stelara ticks away, another biosimilar player has lined up for the piece of the blockbuster's sales pie.

120

120

STAT

FEBRUARY 29, 2024

The dream of being able to pluck a cell therapy off of a freezer shelf and speedily give it to cancer patients is materializing in the cancer world. Now, a new biotech hopes to do the same for patients with neurological conditions.  Kenai Therapeutics closed a $82 million Series A round Thursday co-led by Cure Ventures, The Column Group, and pension fund Alaska Permanent Fund Corp.

132

132

Fierce Healthcare

FEBRUARY 29, 2024

A core provision of the Affordable Care Act (ACA), responsible for ensuring hundreds of millions of Americans receive free access to preventive services, faces a serious legal challenge March 4.

118

118

Fierce Pharma

FEBRUARY 29, 2024

Venture capital firms pitching in on drug development isn’t exactly a new way of doing business for the biopharma industry. | Venture capital firms pitching in on drug development isn’t exactly a new way of doing business for the biopharma industry. But a new funding pact between Carlyle’s Abingworth and Gilead Sciences is somewhat unconventional.

118

118

STAT

FEBRUARY 29, 2024

Flu vaccine appears to be offering reasonable levels of protection this winter, with particularly strong levels in children, new data from the Centers for Disease Control and Prevention suggest. The vaccine effectiveness estimates, which showed unusually robust protection of children against influenza B viruses but more modest protection of people aged 65 and older against influenza A viruses, were presented Wednesday at a meeting of the CDC’s expert vaccine panel, the Advisory Committee

Vaccines 113

Vaccines Immunization 113

Fierce Pharma

FEBRUARY 29, 2024

Several months after Societal CDMO launched a restructuring campaign that led to 26 layoffs, the small molecule contract manufacturer has announced it’s being bought by one of its production peers | Several months after Societal CDMO launched a restructuring campaign that led to 26 layoffs, the small molecule contract manufacturer has announced it’s being bought by one of its production peers in Florida.

115

115

pharmaphorum

FEBRUARY 29, 2024

Explore the impact of the Inflation Reduction Act (IRA) on drug prices and negotiations within the life sciences industry, as it stands on the threshold of change. Gain insights into the potential outcomes and implications of this legislation.

112

112

Digital Pharmacist

FEBRUARY 29, 2024

Did you know March is National Nutrition Month ? National Nutrition Month is an annual campaign sponsored by the Academy of Nutrition and Dietetics and it’s a great opportunity for local pharmacies to educate their patients on the importance of good nutrition, healthy diets, and exercise. Springtime, March specifically, is an excellent time of year for you to start conversations with your patients about the various foods they’re eating and how they can enhance their diets to improve

Health and Personal Care Stores 111

Health and Personal Care Stores 111

Pharmafile

FEBRUARY 29, 2024

AstraZeneca has announced that Voydeya (danicopan) has been recommended for marketing authorisation in the European Union (EU) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The drug is a first-in-class oral, Factor D inhibitor developed as an add-on to standard-of-care Ultomiris (ravulizumab) or Soliris (eculizumab) for the […] The post AstraZeneca’s Voydeya recommended for approval in EU by CHMP appeared first on Pharmafile.

111

111

pharmaphorum

FEBRUARY 29, 2024

It’s been a couple of months since pharma’s annual JP Morgan Chase Healthcare Conference, where the mood around pharma M&A this year was optimistic, albeit with a few caveats. On today’s podcast, host Jonah Comstock is joined by Cody Powers, principal of portfolio and business development at ZS Associates, to discuss those trends and predictions and how they’re shaking out so far.

110

110

Fierce Pharma

FEBRUARY 29, 2024

Sandoz, after inking a new settlement in a price-fixing case inherited from its former parent Novartis, says it’s taken an encouraging step on its quest to leave “allegations of legacy conduct” in | Sandoz, after inking a new settlement in a price-fixing case inherited from its former parent Novartis, says it’s taken an encouraging step on its quest to leave “allegations of legacy conduct” in the past.

109

109

Pharmacy Times

FEBRUARY 29, 2024

Topical niacinamide stabilizes the skin's outer barrier, reducing water loss and improving moisture levels in the epidermis.

123

123

Drug Store News

FEBRUARY 29, 2024

Simlandi is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the United States.

FDA 128

FDA 128

Fierce Pharma

FEBRUARY 29, 2024

For the second time in four weeks, GSK has settled a personal injury lawsuit in California sta | For the second time in four weeks, GSK has settled a personal injury lawsuit in California state court over the heartburn drug Zantac. The company revealed the dismissal of the case and the agreement in a release Thursday.

105

105

pharmaphorum

FEBRUARY 29, 2024

Palatin Technologies’ therapy for dry eye disease (DED) missed its primary endpoints in a phase 3 trial, knocking investor confidence as it tries to chart a way forward.

107

107

STAT

FEBRUARY 29, 2024

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine.  Sign up here  to receive it in your inbox on Tuesdays and Thursdays. Operation Tweak the IRA commences Two proposals to weaken Medicare’s drug price negotiation program are getting a hearing before a House Energy & Commerce subcommittee today.

104

104

European Pharmaceutical Review

FEBRUARY 29, 2024

Eligible individuals in England and Wales can access the first licensed treatment for amyloid light-chain (AL) amyloidosis on the NHS. The National Institute for Health and Care Excellence (NICE) recommended DARZALEX ® (daratumumab) plus VELCADE ® (bortezomib), cyclophosphamide and dexamethasone (DVCd) as an option for people newly diagnosed with the systemic form of the disease.

Documentation 103

Documentation Pharmaceutical Companies Pharmaceutical Companies 103